Stockreport

Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development [Yahoo! Finance]

Metagenomi, Inc.  (MGX) 
PDF Pre-IND regulatory meeting expected in Q4 2025 with investigational new drug (IND) and clinical trial application (CTA) submissions expected in 4Q 2026 EMERYVILLE, Ca [Read more]